Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 589

Sort by

Sort Order Select

Journal Articles

Successful Bone Marrow Transplantation Using an Immunomyelosuppressive Conditioning in Patients with Severe Congenital Neutropenia: The Results of a Single-Institute

Risa Matsumura, Shiho Nishimura, MD, Yoko Mizoguchi, MD PhD, Mizuka Miki, MD, Maki Taniguchi, MD, Maiko Shimomura, MD PhD, Shuhei Karakawa, MD PhD, Shinji Mochizuki, MD PhD, Takehiko Doi, MD PhD, Hiroshi Kawaguchi, MD PhD, Masao Kobayashi, MD PhD

Blood (2019) 134 (Supplement_1): 1035.

https://doi.org/10.1182/blood-2019-126653

Published: 2019

Journal Articles

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Zeyad Al-Shaibani, MD, Eshrak AL-Shaibani, MD, Mats Remberger, PhD, Wilson Lam, MD, Arjun Law, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Dennis Dong Hwan Kim, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 2046.

https://doi.org/10.1182/blood-2019-124208

Published: 2019

Journal Articles

Prophylactic Donor Lymphocyte Infusion for Relapse Prevention; A Meta-Analysis

Kittika Poonsombudlert, MD, Jakrin Kewcharoen, MD, Chattip Prueksapraopong, MD, Limpruttidham Nath, MD MPH

Blood (2019) 134 (Supplement_1): 2017.

https://doi.org/10.1182/blood-2019-121379

Published: 2019

Journal Articles

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Odelia Amit, MD, Yael Bar-On, MD, Galit Perets, MD, Lena Atlas, Liat Shargian, MD, Moshe Yeshurun, MD, Bruria Yachini, RN, Chen Karni, RN, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 2018.

https://doi.org/10.1182/blood-2019-126999

Published: 2019

Journal Articles

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Jimin Shi, MD, Liqin Cao, MD, Yi Luo, MD, Yanmin Zhao, MD, Yamin Tan, MD, Jian Yu, MD, Xiaoyu Lai, MD, Yuanyuan Zhu, MD, Yongxian Hu, MD, Jingsong He, MD, Jie Sun, MD, Weiyan Zheng, MD, Guoqing Wei, MD, He Huang

Blood (2019) 134 (Supplement_1): 2668.

https://doi.org/10.1182/blood-2019-127594

Published: 2019

Journal Articles

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 698.

https://doi.org/10.1182/blood-2019-125802

Published: 2019

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

William C. McManigle, MD, Rachel A. DiCioccio, BS, Sarah Anand, MD, Zhiguo Li, PhD, Jonathan C Poe, PhD, Krista R. Nichols, RN, MSN, AOCNS, Amy N. Suthers, PhD, Wei Jia, MD PhD, Kelly Corbet, BS, Megan Covington, BS, Julia Lloyd-Cowden, BS, Richard D. Lopez, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Cristina Gasparetto, MD, Anthony D. Sung, MD, Nelson J. Chao, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 4521.

https://doi.org/10.1182/blood-2019-130742

Published: 2019

Journal Articles

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Thierry Guillaume, MD PhD, Pierre Peterlin, Sylvain Thepot, MD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Sylvie François, MD, Corentin Orvain, Yannick Le Bris, PharmD, Clémentine Fronteau, PharmD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 4555.

https://doi.org/10.1182/blood-2019-123402

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts

Fouzia N., Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Anu Korula, MD DM, Kavitha M Lakshmi, MSc, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4537.

https://doi.org/10.1182/blood-2019-130491

Published: 2019

Journal Articles

Elimination of Acute GvHD with Three Doses of Abatacept Prophylaxis Combined with Post-Transplant Cyclophosphamide after Myeloablative Treosulfan-Based Conditioning in the HLA Identical Sibling and Unrelated (10-12/12) Peripheral Blood Stem Cell Donor Setting: Improved Safety and Efficacy Compared to Alemtuzumab Prophylaxis

Amit Patel, MBBS,PhDFRCPath,MRCP, Jun Yong, MBChB, MRCP(UK)

Blood (2019) 134 (Supplement_1): 4540.

https://doi.org/10.1182/blood-2019-130184

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Magalie Joris, Delphine Lebon, MD, Amandine Charbonnier, MD, Pierre Morel, MD, Berengere Gruson, MD, Alexis Caulier, MD, Caroline Delette, MD, Marie-Noëlle Lacassagne, Nicolas Guillaume, Loïc Garçon, Jean-Pierre Marolleau, MD PhD

Blood (2019) 134 (Supplement_1): 4600.

https://doi.org/10.1182/blood-2019-131314

Published: 2019

Journal Articles

Clinical Factors and Prognosis of Anti-Gvhd Treatment or Not, Pre-Endoscopically, in Children with Suspected Gastrointestinal Gvhd

Thomas Mårtensson, MD, Mellgren Karin, Sr., MD PhD Professor, Toporski Jacek, MD Associate professor, Johan Arvidson, MD PhD, Thomas Casswall, Associate professor, Britt Gustafsson, MD PhD

Blood (2019) 134 (Supplement_1): 5685.

https://doi.org/10.1182/blood-2019-121903

Published: 2019

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Off-Label Use of Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia: A Single Institution Experience

Daria Gaut, MD, Aaron Burkenroad, MD, Tuyen Duong, Jesse Feammelli, PharmD, Joshua Sasine, MD PhD, Gary J. Schiller, MD

Blood (2019) 134 (Supplement_1): 5133.

https://doi.org/10.1182/blood-2019-123071

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Swati Naik, MBBS, Olive S. Eckstein, MD, Ghadir Sasa, MD, Robert A. Krance, MD, Carl E. Allen, MD PhD, Helen E. Heslop, MD DSc, Caridad A. Martinez, MD

Blood (2019) 134 (Supplement_1): 3273.

https://doi.org/10.1182/blood-2019-132120

Published: 2019

Journal Articles

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Liu Hui, MD, Li Xuan, MD, Ren Lin, MD, Lan Deng, MD PhD, Fen Huang, MD, Zhiping Fan, MD, Danian Nie, MD, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, MD, Jieyu Ye, MD PhD, Hua Jin, Dongjun Lin, MD, Liping MA, MD, Jing Sun, MD, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 3303.

https://doi.org/10.1182/blood-2019-126901

Published: 2019

NARROW

Successful Bone Marrow Transplantation Using an Immunomyelosuppressive Conditioning in Patients with Severe Congenital Neutropenia: The Results of a Single-Institute

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Prophylactic Donor Lymphocyte Infusion for Relapse Prevention; A Meta-Analysis

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Clinical Factors and Prognosis of Anti-Gvhd Treatment or Not, Pre-Endoscopically, in Children with Suspected Gastrointestinal Gvhd

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Off-Label Use of Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia: A Single Institution Experience

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only